m6A Regulator-Mediated Methylation Modification Patterns and Characterisation of Tumour Microenvironment Infiltration in Non-Small Cell Lung Cancer

Abstract

Purpose The role of RNA N6-methyladenosine (m 6 A) modification in the progression of multiple tumours and the tumour microenvironment (TME) has been progressively demonstrated and promises a new direction for tumour therapy. However, there have been no reports on systematic analyses of RNA m 6 A modification in TME in non-small cell lung cancer (NSCLC). Patients and Methods In this study, we used unsupervised cluster analysis to identify three m 6 A modification patterns of 28 m 6 A regulators and three m 6 A gene signature subgroups of commonly differentially expressed genes (co-DEGs) in the three m 6 A modification patterns. Quantifying these subtypes using the ssGSEA and ESTIMATE algorithms to characterise the tumour immune microenvironment (TIME) in NSCLC. Based on the principal component analysis (PCA), we used co-DEGs to construct m 6 A scores to analyse the characteristics of m 6 A modifications in individual patients and assessed the practical clinical utility of m 6 A scores using a nomogram for survival prediction. Results A total of 28 m 6 A regulators in 1210 NSCLC samples were mainly enriched in RNA modification and metabolic biological processes. The three following m 6 A modification patterns were identified based on the role of the 28 m 6 A regulators in TME: immune inflammation, immune evasion and immune desert. The m 6 A scores calculated based on co-DEGs in these modification patterns were significantly positively correlated with immune infiltration and significantly negatively correlated with tumour mutational burden (TMB). Survival was significantly better in the high-m 6 A-score group than in the low-m 6 A-score group, and the m 6 A score could be used as an independent favourable prognostic factor. In addition, assessment of both immune checkpoint inhibitors (ICIs) and immunophenoscore (IPS) revealed a better immunotherapeutic effect in the high-m 6 A-score group. Conclusion The modification characteristics of 28 m 6 A regulators in the TIME of NSCLC were analysed from a comprehensive to an individual basis, which may facilitate the development of more effective clinical immunotherapeutic strategies.

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

“…Analysis of correlation between the levels of CD69 and SBK1, and infiltrating immune cells and IPS. predict response to CTLA-4 and PD-1 blockade and has been used in an increasing number of studies (52)(53)(54). Here, we show that in various tumors, IPS correlates positively and negatively with CD69 and SBK1 expression levels, respectively.…”

Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma

“…The complexity of immune cell infiltration in the tumor microenvironment is one of the leading causes of LUAD treatment efficacy. According to bioinformatics analysis studies, m6A regulators are correlated with tumor prognosis and the immune microenvironment (Fan et al, 2022;Xiong et al, 2022). Two m5C modification patterns had different immune cell-infiltrating subtypes, illustrating that m5C might regulate the LUAD immune microenvironment (Chen et al, 2021b).…”

Role of WTAP in Cancer: From Mechanisms to the Therapeutic Potential

“…However, there are no reports yet on the regulatory mechanisms of WTAP in tumor immunity, one of the tumor hallmarks. Studies have revealed that the tumor microenvironment of patients can be classified into ‘immunoinflammatory’, ‘immune evasion’, and ‘immunodesert’ based on m 6 A-regulated gene expression by unsupervised clustering analysis [ 159 , 160 , 161 ]. Different immune-system phenotypes have different immunotherapeutic effects, and choosing the appropriate treatment plan according to different phenotypes is in line with the modern concept of precision therapy.…”